Scinai Immunotherapeutics Ltd.
SCNIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeScinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. At a $1.3M market cap, Scinai Immunotherapeutics Ltd. ranks as a micro-cap company within healthcare. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Market Cap
$1.3M
Beta
2.08
P/E (TTM)
0.07
P/E (Fwd)
—
EPS (TTM)
$27.92
EPS (Fwd)
—
ROE
-26.5%
ROA
-36.1%
Cash
$2.7M
Total Debt
$3.6M
Free CF
-$3.7M
52W Change
-87.7%
Annual Financials
Cash vs Debt
Where SCNI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SCNI finished 53.48% below its 150-day moving average ($5.03) and 61.45% below its 200-day moving average ($6.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCNI overbought or oversold?
At the September 3, 2026 close, SCNI's RSI(14) was 48.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Scinai Immunotherapeutics Ltd. carries $3.6M in total debt against $2.7M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$3.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -26.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Scinai Immunotherapeutics Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SCNI.